David Amsellem

Stock Analyst at Piper Sandler

(1.1)
# 1650
Out of 5,319 analysts
180
Total ratings
47.00%
Success rate
2.41%
Average return
42 Stocks
Name Action Price Target Current % Upside Ratings Updated
CORT Corcept Therapeutics
Maintains: Overweight
128 131
62.24 110.48% 7 Apr 3, 2025
AMPH Amphastar Pharma
Maintains: Neutral
36 32
23.35 37.04% 7 Mar 21, 2025
OPTN OptiNose
Downgrades: Neutral
15 9
9.17 -1.85% 3 Mar 21, 2025
XERS Xeris Biopharma Hold...
Reiterates: Neutral
3 4
4.11 -2.68% 5 Mar 7, 2025
INDV Indivior
Maintains: Overweight
16 13
9.01 44.28% 5 Mar 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
14 10
7.56 32.28% 7 Mar 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
163 176
102.78 71.24% 10 Feb 26, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
310 329
277.29 18.65% 2 Feb 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
37 36
27.01 33.28% 7 Feb 4, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
23 30
13.65 119.78% 10 Jan 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
107 132
n/a n/a 1 Jan 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
24 13
8.03 61.89% 5 Jan 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
26 9
7.43 21.13% 1 Jan 2, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
160 160
101.38 57.82% 8 Dec 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
9 11
7.36 49.46% 4 Nov 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
38 37
27 37.04% 7 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
68
69.21 -1.75% 1 Oct 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
41 36
30.76 17.04% 12 Sep 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
11 6
n/a n/a 8 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
9 3
5.1 -41.18% 7 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
42 42
24.65 70.39% 7 Jul 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
22 24
11.12 115.83% 5 Apr 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
10
2.51 298.41% 1 Apr 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
20 21
0.73 2776.71% 3 Feb 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
90 113
104.46 8.18% 3 Jan 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
33 45
n/a n/a 2 Dec 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
432 36
5.32 576.69% 3 Nov 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
72 42
28.46 47.58% 3 Oct 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
26 17
n/a n/a 3 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
285
n/a n/a 1 Jan 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
90 110
n/a n/a 5 Dec 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
3750 250
n/a n/a 2 May 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
6 6
n/a n/a 2 Apr 14, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
5 3
n/a n/a 5 Mar 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
5 6
n/a n/a 2 Feb 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 8
n/a n/a 1 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
23 17
n/a n/a 1 Apr 15, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
9
n/a n/a 4 Oct 17, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
n/a
n/a n/a 2 Mar 9, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
n/a
n/a n/a 2 Jul 18, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
n/a
n/a n/a 5 May 10, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
12
n/a n/a 1 Dec 19, 2016